Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Two of DPUK's team awarded Professorships

DPUK is delighted to announce that two of its research team have been awarded Professorships. Dr. Sarah Bauermeister and Dr. Ludovica Griffanti have both been appointed as Associate Professors by the University of Oxford.

We are taking bookings for our next DATATHON!


DPUK's next Datathon will be running from June 26-30 with a theme of cognitive testing.

Great Minds live event to hear about environmental risk factors for dementia

Great Minds is holding an event for its health study volunteers on June 1st in west London. The theme for the afternoon is 'Environmental Factors for Dementia'.

New drug can slow Alzheimers - DPUK's reaction


In a groundbreaking study, Eli Lilly Pharmaceutical has released Donanemab, a new drug that has shown promising results in slowing down cognitive decline in patients with early Alzheimer's disease.

Pippa Watson, Research Assistant, shares her experience working at DPUK

A conversation with Pippa Watson about her work experience as a Research Assistant at DPUK

Making translation in dementia research easier, better and faster

Dementias Platform UK has published its annual report for 2023.

DPUK researcher plans Not Just A Missing Number study by and for trans people and the wider LGBTQIA+ community

DPUK are piloting a new project centring LGBTQIA+ people, to establish a cohort with mainly trans participants for longitudinal studies and to better understand how we characterise gender in our data curation.

MRC grants 2 year costed extension to DPUK’s Deep and Frequent Phenotyping study

Medical Research Council have awarded DPUK’s Deep and Frequent Phenotyping (DFP) study an additional 2 years of funding, supporting work into identifying a set of biomarkers that identify early Alzheimer’s disease

Dementias Platform UK Secures £2.2 million funding from the Alzheimer’s Disease Data Initiative to improve dementia research

Dementias Platform UK (DPUK) has secured £2.2 million from the Alzheimer’s Disease Data Initiative (ADDI) for its work in bridging the gaps between discoveries in the lab, trials and new treatments for dementia.

DPUK launches ground-breaking new Imaging Hub


A new brain imaging hub has been launched by Dementias Platform UK’s Data Portal giving researchers unique access to scans, together with phenotypic and genomic data enabling more complex research analysis into dementia.

Art workshops for over-50s from African and Caribbean communities

People from African and Caribbean communities are underrepresented in dementia research. 'Your Beautiful Brain' is combatting this disparity by involving prominent African and Caribbean artists and dementia researchers working together to deliver art workshops for community members.

Testing for hearing loss could 'reduce Dementia risk' later in life


Research by Dr. Sarah Bauermeister of Dementias Platform UK at the Department of Psychiatry, University of Oxford, into hearing loss and its impacts on the progress of dementia in later life has featured in extensive media coverage of a Brain Health Check-In tool created by Alzheimer's Research UK.

DPUK welcomes government’s £50m investment in MND research

The pledge of £3 million investment by the Medical Research Council towards a translational accelerator will enable the MND community to work in partnership with Dementias Platform UK and the UK Dementia Research Institute.

DPUK-funded study shows symptoms for Alzheimer’s can be predicted in preclinical models

Oxford University researchers have recently established that laboratory models of Alzheimer’s can reflect in-life clinical symptoms. The team found that nerve cells created in the laboratory from Alzheimer’s disease stem cells reacted to amyloid proteins in a similar way in which the brains of the same Alzheimer’s disease patients reacted to high amyloid protein burden load.

Comment: Professor Bart De Strooper steps down as Director of the UK Dementia Research Institute

After six years in his role, Prof De Strooper will now return full time to focus on his research on Alzheimer’s disease. DPUK is delighted that he and his lab will continue to work towards translational neuroscience and dementia research.

New report signposts global dementia data assets for benefit of researchers

Dementias Platform UK (DPUK) today launches its new ‘Data Landscape Report’ – the most comprehensive overview to date of available dementia data assets worldwide.

Cumulative life adversity impacts cognition in later adulthood

New research reveals the association between cumulative life course adversity, depression, and cognitive performance. The findings are published in the scientific journal Nature Scientific Reports.

Digital healthcare company Five Lives joins DPUK consortium as industry partner

DPUK is delighted to welcome the health technology company Five Lives as its newest industry partner.

Reaction: UK government confirms major new funding for dementia research

The UK government has announced the launch of a ‘national mission’ to tackle dementia, pledging again to double research funding to £160m per year by 2024.

Diadem partners with DPUK to advance diagnosis and treatment of Alzheimer’s disease

Diadem SpA, a company developing AlzoSure Predict, the first blood-based test for the early prediction of progression to Alzheimer’s disease, has joined DPUK as an industry partner.

Load More